331.61

1.32% 4.31

Krystal Biotech Inc (KRYS)

Overview News Price History Option Chain Financials Discussions Forecast

Krystal Biotech Inc stock is traded at $331.61, with a volume of 196.95K. It is up +1.32% in the last 24 hours and down -4.73% over the past month. Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.

Previous Close:

$327.30

Open:

$326.55

24h Volume:

196.95K

Relative Volume:

0.67

Market Cap:

$9.82B

Revenue:

$417.30M

Net Income/Loss:

$225.03M

P/E Ratio:

44.32

EPS:

7.4815

Net Cash Flow:

$237.38M

1W Performance:

+2.89%

1M Performance:

-4.73%

6M Performance:

+28.37%

1Y Performance:

+75.68%

1-Day Range:

$323.87

$333.56

1-Week Range:

$319.58

$339.69

52-Week Range:

$179.19

$382.54

Krystal Biotech Inc Stock (KRYS) Company Profile

Name

Krystal Biotech Inc

Sector

Healthcare (1050)

Industry

Biotechnology (591)

Phone

(412) 586-5830

Address

2100 WHARTON STREET, PITTSBURGH, PA

Employee

295

Twitter

@KrystalBiotech

Next Earnings Date

2026-11-02

Latest SEC Filings

KRYS's Discussions on Twitter

Compare KRYS vs VRTX, MRNA, REGN, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KRYS Krystal Biotech Inc	331.61	9.82B	417.30M	225.03M	237.38M	7.4815
VRTX Vertex Pharmaceuticals Inc	510.08	129.29B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	225.00	89.83B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	746.54	76.86B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	825.03	51.88B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.76	40.67B	742.00K	-1.37B	-1.07B	-7.0731

Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-26	Resumed	Goldman	Buy
Aug-14-26	Initiated	RBC Capital Mkts	Outperform
Mar-27-26	Initiated	Wolfe Research	Peer Perform
Jan-06-26	Upgrade	Citigroup	Neutral → Buy
Mar-05-25	Initiated	Jefferies	Buy
Aug-06-24	Downgrade	Citigroup	Buy → Neutral
Nov-20-23	Initiated	Goldman	Buy
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-12-23	Initiated	Citigroup	Buy
Sep-07-23	Initiated	Berenberg	Buy
Apr-18-23	Initiated	Stifel	Buy
Feb-28-23	Upgrade	Goldman	Neutral → Buy
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-18-22	Initiated	BofA Securities	Buy
Jul-20-21	Upgrade	Goldman	Neutral → Buy
Sep-18-20	Initiated	B. Riley FBR	Buy
Jun-04-20	Initiated	Evercore ISI	Outperform
Sep-24-19	Initiated	Goldman	Neutral
Aug-06-19	Reiterated	H.C. Wainwright	Buy
Jun-24-19	Reiterated	Chardan Capital Markets	Buy
Jun-24-19	Reiterated	H.C. Wainwright	Buy
May-30-19	Initiated	Guggenheim	Buy
Sep-11-18	Initiated	Cantor Fitzgerald	Overweight

View All

Krystal Biotech Inc Stock (KRYS) Latest News

Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants Director Sutherland Everett Rand 1,658 Derivative Securities - Kalkine Media

Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants Director Janney Daniel 1,658 Derivative Securities at Zero Cost - Kalkine Media

Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Catherine Mazzacco - Kalkine Media

Sep 17, 2026

Krystal Biotech (NASDAQ: KRYS) Grants 1,658 Derivative Securities to Director Mason Christopher - Kalkine Media

Sep 17, 2026

Sep 16, 2026

Director at Krystal Biotech (KRYS) gets new stock options and RSUs - Stock Titan

Sep 16, 2026

Krystal Biotech at Cantor healthcare conference: pipeline gains pace By Investing.com - Investing.com Canada

Sep 10, 2026

KRYS: International expansion and pipeline progress set the stage for multi-product growth - TradingView

Sep 10, 2026

Krystal Biotech at Cantor healthcare conference: pipeline gains pace - Investing.com

Sep 10, 2026

Here’s How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years - Benzinga

Sep 10, 2026

Sep 08, 2026

Krystal Biotech CEO Krishnan Krish S Sells 25,000 Shares at Prices Up to $366.56 on September 4, 2026 - Kalkine Media

Sep 08, 2026

Krystal Biotech President Krishnan Suma Disposes of 25,000 Shares at $354.54-$366.56 (NASDAQ: KRYS) - Kalkine Media

Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - marketscreener.com

Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,982,986, According to a Recent SEC Filing - marketscreener.com

Sep 08, 2026

Krystal Biotech Insider Sold Shares Worth $8,983,084, According to a Recent SEC Filing - Yahoo Finance

Sep 08, 2026

Sep 07, 2026

Top insider buys and sells disclosed for Friday - Investing.com

Sep 07, 2026